ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2016
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 58 citations in OpenAlex.
- Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits.Journal of neurology, neurosurgery, and psychiatry · 2022Trial
- Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGJournal of neurology, neurosurgery, and psychiatry · 2020Trial
- The role of immunotherapy in a refractory case of acute hemorrhagic leukoencephalitis in a pediatric patient.SAGE open medical case reports · 2025Article
- Vitamin C and MEK Inhibitor PD0325901 Synergistically Promote Oligodendrocytes Generation by Promoting DNA Demethylation.Molecules (Basel, Switzerland) · 2024Article
- Management and outcomes of pediatric optic neuritis in a tertiary hospital in Riyadh, Saudi Arabia: a retrospective study.BMC neurology · 2024Article
- Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS).Immunity & ageing : I & A · 2024Review
- Clinical, radiological, therapeutic and prognostic differences between MOG-seropositive and MOG-seronegative pediatric acute disseminated encephalomyelitis patients: a retrospective cohort study.Frontiers in neuroscience · 2023Article
- Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder.Frontiers in immunology · 2022Article
- Management of pediatric post-infectious neurological syndromes.Italian journal of pediatrics · 2021Article
- Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review.International journal of molecular sciences · 2020Review
- Current Advances in Pediatric Onset Multiple Sclerosis.Biomedicines · 2020Review
- Update on Pediatric Optic Neuritis.Current neurology and neuroscience reports · 2020Review
- Acute Disseminated Encephalomyelitis: An Unusual Presentation of Human Immunodeficiency Virus Infection.Case reports in infectious diseases · 2020Article
- Acute Transverse and Flaccid Myelitis in Children.Current treatment options in neurology · 2019Review
- Update on pediatric optic neuritis.Current opinion in ophthalmology · 2019Review
- Cerebral autoinflammatory disease treated with anakinra.Annals of clinical and translational neurology · 2018Article
- Article
- Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired pediatric demyelinating diseases manifest acutely with optic neuritis, transverse myelitis, acute disseminated encephalomyelitis, or with various other acute deficits in focal or polyfocal areas of the central nervous system. Patients may experience a monophasic illness (as in the case of acute disseminated encephalomyelitis) or one that may manifest as a chronic, relapsing disease [e.g., multiple sclerosis (MS)]. The diagnosis of pediatric MS and other demyelinating disorders of childhood has been facilitated by consensus statements regarding diagnostic definitions. Treatment of pediatric MS has been modeled after data obtained from clinical trials in adult-onset MS. There are now an increasing number of new therapeutic agents for MS, and many will be formally studied for use in pediatric patients. There are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss acute management as well as chronic immunotherapies in acquired pediatric demyelination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.